Verici Dx (Verici Dx) ROE % Adjusted to Book Value : -28.07% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx ROE % Adjusted to Book Value?

Verici Dx's ROE % for the quarter that ended in Jun. 2023 was -115.91%. Verici Dx's PB Ratio for the quarter that ended in Jun. 2023 was 4.13. Verici Dx's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was -28.07%.

Verici Dx ROE % Adjusted to Book Value Historical Data

The historical data trend for Verici Dx's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx ROE % Adjusted to Book Value Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

-47.14

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
ROE % Adjusted to Book Value	-	-	-25.39	-39.61	-28.07

Competitive Comparison of Verici Dx's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Verici Dx's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Verici Dx's ROE % Adjusted to Book Value falls into.

Verici Dx ROE % Adjusted to Book Value Calculation

Verici Dx's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-97.11%	/	2.06
	=	-47.14%

Verici Dx's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-115.91%	/	4.13
	=	-28.07%

Verici Dx ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Verici Dx's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines